Furthermore, methylated RASSF1A and neurogenic differentiation 1 gene promoters in serum are candidate biomarkers for monitoring the efficacy of adjuvant therapy in breast cancer patients (Fiegl et al, 2005, 2008). The gene discussed is RASSF1; the disease is breast carcinoma.